G
Goedele De Smedt
Researcher at Janssen Pharmaceutica
Publications - 25
Citations - 2082
Goedele De Smedt is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Etravirine & Tolerability. The author has an hindex of 15, co-authored 25 publications receiving 2050 citations. Previous affiliations of Goedele De Smedt include Tibotec.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Adriano Lazzarin,Thomas B. Campbell,Bonaventura Clotet,Margaret Johnson,Christine Katlama,Arend Moll,William J. Towner,Benoit Trottier,Monika Peeters,Johan Vingerhoets,Goedele De Smedt,Benny Baeten,Greet Beets,Rekha Sinha,Brian Woodfall +14 more
TL;DR: In treatment-experienced patients with NNRTI resistance, treatment with TMC 125 achieved better virological suppression at week 24 than did placebo, and the safety and tolerability profile of TMC125 was generally comparable with placebo.
Journal ArticleDOI
Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C: The Randomized PILLAR Study
Michael W. Fried,Maria Buti,Gregory J. Dore,Robert Flisiak,Peter Ferenci,Ira M. Jacobson,Patrick Marcellin,Michael Manns,Igor G. Nikitin,Fred Poordad,Morris Sherman,Stefan Zeuzem,Jane Scott,L. Gilles,Oliver Lenz,Monika Peeters,V. Sekar,Goedele De Smedt,M. Beumont-Mauviel +18 more
TL;DR: SMV QD in combination with Peg‐IFN and RBV significantly improves SVR rates, compared with Peg-IFNand RBV alone, and allows the majority of patients to shorten their therapy duration to 24 weeks.
Journal ArticleDOI
Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
Stefan Zeuzem,Thomas Berg,Edward Gane,Peter Ferenci,Graham R. Foster,Michael W. Fried,Christophe Hézode,Gideon M. Hirschfield,Ira M. Jacobson,Igor G. Nikitin,Paul J. Pockros,Fred Poordad,Jane Scott,Oliver Lenz,Monika Peeters,V. Sekar,Goedele De Smedt,Rekha Sinha,M. Beumont-Mauviel +18 more
TL;DR: In treatment-experienced patients, 12, 24, or 48 weeks simeprevir in combination with 48 weeks PegIFn and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, andRBV and was generally well tolerated.
Journal ArticleDOI
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies
Johan Vingerhoets,Lotke Tambuyzer,Hilde Azijn,Annemie Hoogstoel,Steven Nijs,Monika Peeters,Marie-Pierre de Béthune,Goedele De Smedt,Brian Woodfall,Gaston Picchio +9 more
TL;DR: The weighted genotypic scoring algorithm optimizes resistance interpretations for etravirine and guides treatment decisions regarding its use in treatment-experienced patients.
Journal ArticleDOI
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Christine Katlama,Richard Haubrich,Jacob Lalezari,Adriano Lazzarin,José Valdez Madruga,Jean-Michel Molina,Mauro Schechter,Monika Peeters,Gaston Picchio,Johan Vingerhoets,Brian Woodfall,Goedele De Smedt +11 more
TL;DR: At 48 weeks, treatment-experienced patients receiving etravirineplus background regimen had statistically superior and durable virologic responses (viral load less than 50 copies/ml) than those receiving placebo plus background regimen, with comparable tolerability and no new safety signals reported since week 24.